Abbott Laboratories (ABT) Stock

Abbott Laboratories trades at a P/E ratio of 17.45, which is near the market average of approximately 20, suggesting the market views it as fairly valued relative to its earnings. Looking ahead, the forward P/E of 26.11 is higher than the current P/E, indicating analysts expect earnings to decline over the next year. The PEG ratio of 4.17 indicates a premium valuation even accounting for growth.

With a beta of 0.74, Abbott Laboratories is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 4.79 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Abbott Laboratories achieves a profit margin of 31.90%, meaning it retains $31.90 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 18.10% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 30.60% and ROA at 6.38%, the company generates strong returns on invested capital.

Abbott Laboratories's revenue grew by 4.00% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 8.60% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against PHARMACEUTICAL PREPARATIONS industry averages for proper context.

Abbott Laboratories offers a dividend yield of 1.76%, paying $2.28 per share annually. This modest yield below 2% suggests the company prioritizes growth investments over current income. While the dividend provides some return, investors are likely attracted more by capital appreciation potential than income generation. To receive the next dividend, shares must be purchased before the ex-dividend date of 7/15/2025.

The dividend sustainability can be assessed through the payout ratio - Abbott Laboratories pays $2.28 per share in dividends against earnings of $7.70 per share, resulting in a payout ratio of 29.61%. This conservative payout below 30% indicates excellent dividend safety with substantial room for future increases. The company retains most earnings for growth while still rewarding shareholders. The next dividend payment is scheduled for 8/15/2025.

Abbott Laboratories has a market capitalization of $233.80B, classifying it as a mega-cap stock (over $200B). These are the largest, most established companies globally, typically offering stability and liquidity but with more modest growth potential. Mega-caps often pay dividends and weather economic downturns better than smaller companies. With 1.74B shares outstanding, the company's ownership is widely distributed. As a major player in the PHARMACEUTICAL PREPARATIONS industry, it competes with other firms in this sector.

Abbott Laboratories's book value per share is $28.05, while the current stock price is $131.02, resulting in a price-to-book (P/B) ratio of 4.67. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

28 analysts cover ABT with 68% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $141.32 implies 7.9% upside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:7 Strong Buy, 12 Buy, 9 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

RSI data is not available for this stock.

MACD and moving average data are not available for this stock.